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Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting spinal cord motoneurons
(MN) with an associative connection to Frontotemporal Lobar Dementia (FTLD). The endoplasmic re-
ticulum (ER) bound Sigma-1 Receptor (S1R) chaperone protein localizes to specialized ER cisternae
within 10 nm of the plasma membrane in spinal cord ventral horn cholinergic post synaptic C-terminals.
Removal of the S1R gene in the Superoxide Dismutase-1 (SOD-1) mouse model of ALS exacerbated the
neurodegenerative condition and resulted in a signiﬁcantly reduced longevity when compared to the
SOD-1/S1R wild type (WT) mouse. The proposed amelioration of the ALS phenotype by the S1R is likely
due to a “brake” on excitation of the MN as evidenced by a reduction in action potential generation in the
MN of the WT when compared to the S1R KO mouse MN. Although the precise signal transduction
pathway(s) regulated by the S1R in the MN has/have not been elucidated at present, it is likely that direct
or indirect functional interactions occur between the S1R in the ER cisternae with voltage gated po-
tassium channels and/or with muscarinic M2 receptor signaling in the post synaptic plasma membrane.
Possible mechanisms for regulation of MN excitability by S1R are discussed.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative
disease primarily targeting spinal cord motoneurons (MN) (1,2).
Often it associates with other neurodegenerative diseases such as
Frontotemporal Lobar Dementia (FTLD). ALS can occur due to ge-
netic mutations or environmental factors. Familial cases represent
only about 10 percent of ALS cases and these are linked to muta-
tions in particular proteins that eventually result in dysfunction and
death of MN (2). Mutations of more than 100 genes result in the
establishment of ALS (3), including increasing expansion of
GGGGCC hexanucleotide repeats and mutations in superoxide
dismutase-1 protein (SOD1), the TAR-DNA binding protein,TDP43,
and the RNA-binding protein, FUS. Usually ALS is diagnosed in
humans after the age of 40, but in some cases it can occur in ju-
veniles (4,5). There is no cure for ALS and the best known protector,
riluzole, which, in part, reduces levels of the excitatoryacological Society.
. Production and hosting by Elseneurotransmitter, glutamate, from neuronal synapses (6,7) can only
extend human life for a few months.
Synaptic innervation ofMN is complex (8). Synapses involving all
known major neurotransmitters innervate MN and have been
classiﬁed as S, M, T, F, P and C-boutons/terminals (9) (boutons refer
to presynaptic; terminals refer to postsynaptic). Presynaptic C-
boutons originate from interneurons whose cell bodies are located
close to the central canal of the spinal cord, between laminae VII and
X (10). Diverse and even controversial changes of C-bouton
morphology have been reported in animal models of ALS and spinal
cord injury (11e14). C-terminals are cholinergic postsynaptic sites
with a unique ultrastructure seen at the electron microscopy level.
They are referred to as “C” because of the subsurface cisternae of
smooth endoplasmic reticulum adjacent to the plasma membrane
(PM) and are giant synapses (2e7 mm in diameter, but somewhat
vary depend on the species) found only on soma and proximal
dendrites of MN. The presence of such subsurface cisternae in syn-
aptic terminals larger than 2 mm can serve as amarker for MNs (15).
2. The S1R and neurodegenerative diseases
The Sigma-1 Receptor (S1R) chaperone protein (16) has been
shown to be a target for the treatment of a variety of chronicvier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Sigma-1 receptor reduces motoneuron excitability and slows ALS progression.
A. Frequency-current relationships in motoneurons of SR1 KO (red) and WT (blue)
mice. A signiﬁcant increase in the slope of FeI relationship was apparent in S1R KO
mice at current intensities > 700 pA (p < 0.05). Bars are ± standard errors. Number of
recordings per intensity is shown above/below standard error bars. B. KaplaneMeyer
end stage curve. Median survival of mice is 186.0 days for ALS S1RWT mice (blue), and
127.0 days for ALS S1R KO mice (red). p < 0.0001; c2 ¼ 32.29. Modiﬁed with copyright
permission from: Mavlyutov et al., Neuroscience 2013; 240:129e34.
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(19), Alzheimers (20), Parkinsons (21), and Huntingtons (22) dis-
eases, schizophrenia (23), stroke (24) and degeneration of retinal
neurons (25,26). Recently, ALS was added to this list (4). It is
remarkable that MN express S1R at the highest levels in the CNS (27,
28). Mutations of the S1R have been found to result in the estab-
lishment of ALS in humans (4). In contrast, genetic knockout of the
S1R in mice did not produce an ALS phenotype (29). S1R knockout
mice on an ALS background, however, showed a faster onset of dis-
ease and decreased longevity (30) while application of S1R ligands
signiﬁcantly extended the lifespan of ALS model mice (31e33).
3. Structural and pharmacological properties of S1R
Initially the S1R was identiﬁed by speciﬁc binding to SKF 10047
(34) and was classiﬁed as an opioid-like receptor, but later exper-
iments showed that the S1R has pharmacological binding proper-
ties distinct from opioid receptors (35). Another sigma receptor, the
Sigma-2 receptor, has been identiﬁed by binding to ditolylgunai-
dine (DTG) (36) although it has not yet been cloned. The cloned S1R
is a protein of 223 amino acids containing two transmembrane
sequences with both the N and C termini on the same side of the
membrane (16,37). The S1R in its puriﬁed form, in vitro, and also the
S1R in vivo, exists in monomeric, dimeric, tetrameric and higher
oligomeric forms (38,39). It has been suggested that the functional
activities of the S1R are linked to S1R agonist and antagonist
alteration of the equilibria between these various forms (38). The C-
terminus (approximately 110 amino acids) in either the dimeric
and/or monomeric form(s) is likely to determine the manner by
which the overall chaperone functions of the S1R are established
with various “client” proteins (37,40e44).
Many synthetic compounds have been characterized as selective
agonists or antagonists for the S1R, (16,45,46). Several endogenous
compounds have been proposed to be S1R ligands, including the
lipid, sphingosine and its derivatives (47), steroids such as DHEA,
progesterone and pregnenolone sulfate (48), and the trace amine,
N, N-dimethyl tryptamine (DMT) (49). It is very possible that
various endogenous compounds regulate the functions of the S1R
in different cells and tissues depend on their availability to spe-
ciﬁcally bind to the S1R (17).
4. Functions of S1R
The S1R has been shown to have a number of chaperone and
client protein-related functions: activation or inhibition of plasma
membrane excitability (50), modulation of G-protein coupled re-
ceptors (GPCRs) (51,52), and ER stress (53,54). Thus to date the
literature shows that the S1R is a multi-tasking protein involved in
a broad cell range of signaling pathways and functions (16,17).
Langa et al (29) demonstrated that the Sigma-1 receptor knockout
mice are fully fertile, viable, and showed no obvious behavioral
phenotypes. This was an interesting result since the loss of the S1R
was expected to cause loss of some crucial biological functions. The
same group did subsequently show that S1R knockout mice had a
diminished response to pain (55). In other studies two additional
important functions have also been well documented; that is,
modulation of ion channel activity (56,57) and ER stress (37). In ER
stress, an unfolded protein response results from the accumulation
of misfolded proteins in the endoplasmic reticulum lumen (58). The
ﬁrst response to ER stress is the activation of intracellular chaper-
ones to refold the misfolded proteins. If the accumulation of
unfolded proteins exceeds the ability of the chaperones to correct
the condition, cellular apoptosis is triggered. Key proteins partici-
pating in the ER stress are BIP, IRE1, eIF1 and PERK (58). To date, the
S1R has been shown to interact with BIP, PERK, and IRE1 andthrough these interactions has been proposed, in part, to alleviate
ER stress (37,59,60). S1R interacts with the IP3 receptor 3 in
mitochondrial-associated membranes (MAM) and modulates cal-
cium ﬂow from the ER into mitochondria, a process important for
the regulation of bioenergetics (37). Through thesemechanisms the
S1R plays a secondary but critical role and acts as a chaperone/
adaptor/modulator of the activities of interacting client proteins. To
date the S1R itself has not been shown to have functional activities
independent of other protein partners.
5. Speciﬁc connections of the S1R to ALS
The S1R is distributed in many mammalian tissues (61,62). In
the central nervous system (CNS) the highest levels of Sigma-1
receptors are found in MN of the spinal cord and brainstem
(27,28). The presence of the S1R in MN is particularly intriguing
because these cells are highly vulnerable to destruction and no
therapy is available to restore MN. Chemicals that induce toxicity
and/or genetic mutations can result in the loss of MNs. It has been
shown (although only in one family) that an E102Q autosomal-
recessive mutation in the S1R results in juvenile ALS (4). Recent
evidence has further linked overexpression of the E102Q S1R in
Neuro2A cells to aggregation of the mutant S1R followed by
reduction in mitochondrial ATP production and mislocalization of
the TAR DNA binding protein, TDP43, from the nucleus to the
cytoplasm. This effect of E102Q mutation could be rescued by
T.A. Mavlyutov et al. / Journal of Pharmacological Sciences 127 (2015) 10e1612addition of methyl pyruvate to maintain mitochondrial ATP pro-
duction (63).
An autosomal recessive phenotype (required mutation on two
alleles) implies that the lack of function of the S1R can establish ALS
in humans. Also, mutation of the 30 untranslated region of the
Sigma-1 receptor gene in humans resulted in ALS and FTLD (64). In
this case it was sufﬁcient to have only one allele mutant for the
appearance of disease. On the other hand S1R knockout mice (that
might be predicted to show a “lack of function”) show no ALS
development. The protective role of S1R in ALS, however, has been
revealed in ALS model mice where the presence of a mutant su-
peroxide dismutase 1 (SOD1 G*93Amousemodel) and a lack of S1RFig. 2. The sigma-1 receptor (green signal in the left and middle panels) and the DMT prod
terminals and juxtaposed to presynaptic cholinergic (ChAT positive) boutons (red). To de
densities of MNs we performed double labeling with antibodies against synaptophysin
synaptophysin-positive synapses are juxtaposed to the sigma-1 receptor. Blue (DAPI stain)
cistern of cholinergic postsynaptic site. Modiﬁed with copyright permission from: Mavlyut(S1R KO), caused exacerbation of disease progression as revealed by
behavioral and longevity experiments (Fig. 1). Moreover, to date, in
two ALS animal mouse models, the speciﬁc S1R ligand, PRE084 and
SA4503 extended lifespan and resulted in the maintenance of
mouse motor skills andMN longevity. These data may demonstrate
a difference between mutations of human and mouse S1Rs since
when mice are stressed a S1R related phenotype is exhibited. The
appearance of the S1R in the MN of ALS model mice has been
somewhat controversial. Diseased MN lose their shape, decrease in
size, and show decreases in synaptic coverage. Abundant S1R in the
diseased MN that survive after ﬁxation have been observed but the
total number of Sigma-1 receptors in the spinal cord are reduceducing enzyme INMT (green in the right panel) are localized to postsynaptic sites of C-
monstrate that the sigma-1 receptor is juxtaposed only to cholinergic postsynaptic
(a universal marker for different types of chemical synapses). Notice that not all
indicates cell nuclei. Lower panel shows localization of sigma-1 receptor in subsurface
ov et al., Neuroscience 2012; 206: 60e80.
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Casas et al (14) found absence of Sigma-1 receptors in diseased
lumbar MN although the use of speciﬁc markers to conﬁrm MN
identity were lacking.6. Subcellular localization and proposed function(s) of the
S1R in motor neurons
The S1R can participate in many different intracellular pathways
(16). To understand the mechanism(s) by which the S1R plays a
neuroprotective role in MN (or generally in other cells), it is
important to know where the S1R is localized in the cell. Using
immunoelectron microscopy we previously showed that the S1R is
localized in subsurface cisternae in C-terminals (Fig. 2). C-terminals
contain Muscarinic type 2 acetylcholine receptors (M2AChR),
voltage gated potassium channels (Kv2.1) and slow potassium (SK)
channels located in the postsynaptic plasma membrane. The
presence of subsurface cisternae in postsynaptic densities is
believed to correlate with observed postsynaptic hyperpolarization
(65e67). In this regard, Kv2.1 and SK channels are able to mediate
after hyperpolarization of cells. Generally it has been proposed that
differential expression of SK2.2 and SK2.3 channels in neurons
distinguish fast or slow type MN (68). Miles et al (10). have shown
in MN that activation of M2AChR results in inhibition of SK chan-
nels, a result that reduces after hyperpolarization and thus in-
creases neuronal excitability. We have shown that the excitability
of MN is higher in S1R knockout mice than in their wild type
counterparts which is consistent with the idea that the absence of
S1R prevents the activation of Kv2.1 and/or SK channels (30)
(Fig. 2). Thus the S1R appears to act as a brake on the excitability
of MN. Many potassium channels are modulated by S1R
(44,69e71). To summarize: 1) in common to many mammalian
cells, the S1R inMN is found in the ER; 2) the S1R is abundant inMN
cholinergic postsynaptic sites; 3) the S1R is enriched in only C-Fig. 3. Diagram showing our hypothesis for the role of the S1R in C-terminals: A. The S1R reg
WT animals the S1R will activate potassium channels resulting in a larger afterhyperpolarizat
afterhyperpolarization results in a higher ﬁring frequency and a stronger muscle contracti
potassium channels in the postsynaptic plasma membrane. B. The enzyme INMT produces t
in a conductance increase in calcium channels, and the subsequent opening of potass
hyperpolarization. C. S1R can directly interact with and modulate potassium channels, re
membrane of C-terminals.terminals, when compared to neurons in general, including many
of the neurons and interneurons of the spinal cord.
7. Speculations regarding S1R mechanism(s) for protecting
motor neurons (Fig. 3)
The S1R in C-terminals is in close physical proximity to Kv2.1
and SK channels making these two channels suitable candidates for
interaction with S1R in postsynaptic membrane of MN. At the
moment, it is unclear how the S1R might activate Kv2.1 and/or SK
channels and thus decrease excitability. It has been shown in other
neuronal cells that S1R canmodulate activities of SK channels and a
variety of Kv type channels (44,71e73). Moreover, it has been
shown that S1R can also form a complex with a variety of G-protein
coupled receptors (GPCRs) and can modulate their activities
(51,52). An accumulation of literature indicates that inhibition of
M2AChR and/or activation of Kv2.1 and/or SK channels in C-ter-
minals should contribute toward reduction of MN excitability
(10,74,75). Thus it remains to be elucidated whether, in MN and
possibly other neurons, the S1R can inhibit the M2AChR directly or
indirectly interfere with Gi signaling with a resultant decrease in
neuronal excitability. As previously stated, M2AChR, Kv2.1, and SK
channels are all known to be located in the plasmamembrane (PM)
(75), while the S1R is located in the subsurface cisternae of C-ter-
minals (28). Physical proximity of the PM and the cisternae in C-
terminals (distance of less than 10 nM) make direct molecular
interaction possible for proteins located in adjacent membranes.
Examples of such interactions between proteins located in the PM
and subsurface cisternae can be found in skeletal muscle, where the
dihydropyridine receptor in the PM directly interacts with the
ryanodine receptor in cisternae, or in cardiomyocytes where the
calcium channel, Orai, located in the PM and STIM-1 located in
cisternae, close to the PM, interact in a functionally relevant
manner (76). In both examples these interactions are important for
enhanced calcium ﬂow. Subsurface cisternae have been consideredulates the activity of potassium channels located in postsynaptic sites of C-terminals. In
ion that reduces the ﬁring frequency in motoneurons. In sigma-1 KO animals, a reduced
on. B and C: Two possible mechanisms showing how S1R can regulate the activity of
he ligand that activates the S1R localized in the subsurface cisternae. Active S1R results
ium channels (SK2 and/or Kv2.1) through calmodulin (CaM), leading to an after-
sulting in an increased conductance of the SK2 and/or Kv2.1 channels in the plasma
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the interaction of S1Rwith the inositol triphosphate type 3 receptor
(IP3R3) to enhance calcium ﬂow to mitochondria (37). Activities of
both Kv2.1 and SK channels are modulated by calcium, ether
directly or indirectly through Ca/calmodulin/calcineurin mecha-
nisms (78,79) (Fig. 3). It is possible that the S1R by chaperoning
IP3Rs can also indirectly inﬂuence these potassium channels via
regulation of calcium release from the cisternae. Thus it is
reasonable to consider that modulation of potassium channels in C-
terminals may partly underlie the mechanism(s) by which the S1R
can reduce excitability of MN. Other possible mechanisms for S1R
protection of MN certainly exist; for example, recently Esquerda
and colleagues have shown that the growth factor Neuregulin-1
that protects MN loss in ALS co-localizes with the S1R in C-termi-
nal cisternae (80) further expanding a possible role for S1R inMN as
a Neuregulin-1 interacting protein.
8. Other possible S1R interactions in C-terminals
1) The S1R, Indole(ethyl)amine N-MethylTransferase (INMT) and
N,N-Dimethyltryptamine (DMT).
As indicated previously, several endogenous compounds have
been shown to bind to the S1R and thus may provide regulation of
S1R activities (16). Although the afﬁnity of these compounds for the
S1R varies considerably, activation of the S1R may depend on the
cellular environments and the local concentrations in various
mammalian tissues. We have shown that N,N-dimethylytrptamine
(DMT) is an agonist for the S1R (49). The relationship between DMT
and the S1R was further reinforced by the demonstration that the
enzyme, Indole(ethyl)amine N-methyltransferase (INMT) that
converts the amino acid tryptophan decarboxylation product,
tryptamine, into DMT, co-localized with the S1R in C-terminals of
the primate MN (81) (Fig. 2). This paradigm shifting observation of
co-localization of S1R and INMT to produce DMT, may be func-
tionally very important to provide high local concentrations of the
agonist due to the close juxtaposition with the S1R. This co-
localization may further be relevant because the afﬁnity of DMT
towards S1R as determined by in vitro experiments is relatively low,
in the micromolar range (49).
2) S1R, Indole(ethyl)amine N-MethylTransferase INMT) and Thio-
EtherMethylTransferase (TEMT)
Recent data indicate (82) that, in contrast to humans, inmice the
primary function of INMT (also known as mouse TEMT) is NOT
methylation of tryptamine, but rather methylation of sulfur, sele-
nium and tellurium containing compounds, presumably for
detoxiﬁcation purposes (83) and for reduction of oxidative stress
(84,85). In addition to its ability to methylate tryptamine, recom-
binant; human INMT (hINMT) can also methylate thiol containing
compounds (such as the endogenous compound, cysteamine and
the synthetic substrate, 2-(methylthio) ethylamine) due to an
alternate TEMT enzyme activity (82). This observation reinforces
the report (63) that the S1Rmutation E102Q that underlies juvenile
ALS (4) causes cytoplasmic aggregation of S1R and oxidative stress
in Neuro2A cells via mitochondrial disruption of ATP synthesis. The
potential oxidative stress reducing properties of the TEMT activity
of INMT is also in complete accord with previous demonstrations
that the S1R reduces oxidative stress in cells (25,54,86). It is
therefore reasonable to conclude that the co-localization of S1R
with INMT/TEMT (81) in primate and human MN may provide
protection by the S1R through both enzyme activities (i.e. forma-
tion of DMT and reduction in oxidative stress via methylation of
thiols and trace metals).3) S1R, Neuregulin-1 and erbB receptors.
The S1R co-localizes in mouse MN C-terminal cisternae with
Neuregulin-1 (80). Neuregulin 1 is a growth factor acting on erbB
receptors which are found on C-boutons. To reach the presynaptic
membrane from the subsurface cisternae, neuregulin 1 is sorted in
an exosomal pathway (80). Levels of Neuregulin-1 are known to be
reduced in MN of human ALS patients and also in SOD1G93A mice
(87). Although a molecular interaction between S1R and
Neuregulin-1 has not been established, it is tempting to speculate
that the S1R serves to chaperone Neuregulin-1 to the subsurface
cisternae of MN. Indeed, the S1R has been also shown to regulate
post-translational processing of growth factors (88).9. Conclusions
The protective roles of S1R in MN of mouse models of ALS have
been conﬁrmed. Although the precise molecular mechanisms un-
derlying these protective roles have not been clearly elucidated at
present, the multi functional nature of the S1R provides an
attractive target for treating ALS. Future human trials will be
needed to show if targeting S1R with selective S1R agonists,
perhaps in combination with appropriate drugs that regulate other
ALS ameliorating signaling pathways, can synergistically protect
MN in Amyotrophic Lateral Sclerosis.Conﬂict of interest
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